MEA / SOBI VP Talks Regional Rare Disease Trends
Ahmad Abu Dahab became the first Middle East employee for Swedish-headquartered haematology, immunology and specialty care player SOBI back in 2012 and now serves as VP for the entire Middle…
Sobi is an international rare disease company headquartered in Stockholm, Sweden dedicated to providing access to innovative treatments for people living with rare diseases.
The Sobi organisation spans 25 countries, delivering treatments to patients in over 60 countries across the globe.
Sobi’s two main business areas are Haemophilia and Specialty Care. Their research and product portfolio is primarily focused on haemophilia, inflammation, and genetic and metabolic diseases.
In Specialty Care, Sobi provides treatments for rare diseases and speciality indications.
Sobi is an integrated biotechnology company with in-house capabilities that encompass the entire value chain, from research to preclinical and clinical development, biologics manufacturing and supply, to patient access and distribution.
Ahmad Abu Dahab became the first Middle East employee for Swedish-headquartered haematology, immunology and specialty care player SOBI back in 2012 and now serves as VP for the entire Middle…
Sobi’s VP and general manager for Spain and Portugal, Pablo De Mora, comments on his experience during the pandemic, the Swedish company’s haematology and immunology portfolio, including its EMA-approved COVID-19…
Assobiotec’s Leonardo Vingiani introduces the key trends shaping the Italian biotech ecosystem today, the steps that the country’s government have taken to foster life sciences innovation, and the areas in…
Elisabeth Svanberg MD, PhD, a seasoned industry expert, having worked for established MNCs such as Serono, BMS & J&J, now sits on the board of Sweden’s national champion SOBI, is…
Aurora Berra, general manager of Sobi Spain and Portugal, highlights her key priorities and the opportunities and challenges inherent in the fragmented Spanish healthcare system. Berra gives insight into the…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering…
Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the…
Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager…
Leonardo Vingiani, Director of Assobiotec, discusses how the country’s biotech industry has evolved since 2009, what areas still need improving and the enormous progress which has been made in unlocking…
Biotechnologies have a significant role to play bringing Italy towards a more knowledge-based economy. What is the economic contribution of the sector today? According to the last Blossom Associati-Assobiotec report…
PharmaBoardroom caught up with Niklas Hedberg at DIA Europe 2024 in Brussels to gauge what more needs to be done ahead of the implementation of European HTA regulation in January…
The recent FDA decision to investigate the serious risk of patients developing new cancers after treatment with CAR-T therapies may have created some bad press around cell and gene therapies,…
Svante Paabo has won the 2022 Nobel Prize in physiology or medicine for his ground-breaking work in paleogenetics. Paabo’s research – which includes sequencing the genome of the Neanderthal for…
Anders Blanck, CEO of LIF, the industry organisation for the research-based pharmaceutical industry in Sweden, describes the Sustainability Strategy that the pharma industry in Sweden is now launching. Central to…
Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international…
In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…
Petter Hartman of the Medicon Valley Alliance, a non-profit membership organisation spanning the Danish-Swedish life science cluster Medicon Valley, introduces the progress of the Alliance from a networking body to…
In a wide-ranging interview, AbbVie’s Linn Mandahl discusses how the reorganisation of Scandinavian operations back in 2018 has put the company back on a growth trajectory in the region. Mandahl…
Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been…
Anders Blanck of Lif, the trade association for the research-based Swedish pharmaceutical industry, outlines the steps already being put in place for Sweden to become a leading country in the…
Niklas Hedberg outlines the role of EUnetHTA as both a network and project built up of national HTAs in Europe, the potential for a continent-wide mandate on health technology assessment,…
Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real…
See our Cookie Privacy Policy Here
